Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
4LSJ9Pf9waKVdPg0
Listen
